APO RESEARCH · REPORT
Influenza Vaccine
Influenza vaccines, also known as flu shots, are vaccines that protect against influenza. A new version of the vaccine is developed twice a year as the influenza virus rapidly changes. Most provide modest to high protection against influenza; however, each year this varies. Evidence in adults over 65 years old is poor. They decrease the number of missed days of work by a half day on average. Vaccinating children may protect those around them.
Product & engineering
Understand the product.
Influenza vaccines, also known as flu shots, are vaccines that protect against influenza. A new version of the vaccine is developed twice a year as the influenza virus rapidly changes. Most provide modest to high protection against influenza; however, each year this varies. Evidence in adults over 65 years old is poor. They decrease the number of missed days of work by a half day on average. Vaccinating children may protect those around them.
Selected research
Industry Research
Influenza Vaccine Industry Research Report 2026
Market perspective
Influenza vaccines, also known as flu shots, are vaccines that protect against influenza. A new version of the vaccine is developed twice a year as the influenza virus rapidly changes. Most provide modest to high protection against influenza; however, each year this varies. Evidence in adults over 65 years old is poor. They decrease the number of missed days of work by a half day on average. Vaccinating children may protect those around them.
Global Influenza Vaccine main players include CSL, GSK, Sanofi Pasteur, Mylan, Hulan Bio, AstraZeneca, CCBIO, etc., totally accounting for about 95% of market. North America is the largest market of Influenza Vaccine, with a share over 55%. As for the types of products, it can be divided into Trivalent Influenza Vaccine and Quadrivalent Influenza Vaccine. The most common product is Quadrivalent Influenza Vaccine, with a share over 95%. In terms of applications, it is widely used in For Children (6 months to 3 years) and For Adults and Children over 3 years. The most application is in Adults and Children over 3 years, with a share over 73%.
Report Scope
Read the full market overview
This report quantifies the global Influenza Vaccine market in terms of revenue (US$ million) and, where applicable, sales volume (M Doses), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/M Doses) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Influenza Vaccine Market by Company
CSL
GSK
Sanofi Pasteur
Mylan
Hulan Bio
AstraZeneca
CCBIO
Influenza Vaccine Segment by Type
Trivalent Influenza Vaccine
Quadrivalent Influenza Vaccine
Influenza Vaccine Segment by Application
For Children (6 months to 3 years)
For Adults and Children over 3 years
Influenza Vaccine Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Influenza Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Influenza Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Influenza Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Influenza Vaccine manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Influenza Vaccine by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Influenza Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Trivalent Influenza Vaccine
- Quadrivalent Influenza Vaccine
Applications
- For Children (6 months to 3 years)
- For Adults and Children over 3 years
Companies covered
- CSL
- GSK
- Sanofi Pasteur
- Mylan
- Hulan Bio
- AstraZeneca
- CCBIO
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Influenza Vaccine Market Size (2021-2032)
- 2.2.2 Global Influenza Vaccine Sales (2021-2032)
- 2.2.3 Global Influenza Vaccine Market Average Price (2021-2032)
- 2.3 Influenza Vaccine by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Trivalent Influenza Vaccine
- 2.3.3 Quadrivalent Influenza Vaccine
- 2.4 Influenza Vaccine by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 For Children (6 months to 3 years)
- 2.4.3 For Adults and Children over 3 years
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Influenza Vaccine Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Influenza Vaccine Sales (M Doses) of Manufacturers (2021-2026)
- 3.3 Global Influenza Vaccine Revenue of Manufacturers (2021-2026)
- 3.4 Global Influenza Vaccine Average Price by Manufacturers (2021-2026)
- 3.5 Global Influenza Vaccine Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Influenza Vaccine, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Influenza Vaccine, Product Type & Application
- 3.8 Global Manufacturers of Influenza Vaccine, Established Date
- 3.9 Global Influenza Vaccine Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 CSL
- 4.1.1 CSL Company Information
- 4.1.2 CSL Business Overview
- 4.1.3 CSL Influenza Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 CSL Influenza Vaccine Product Portfolio
- 4.1.5 CSL Recent Developments
- 4.2 GSK
- 4.2.1 GSK Company Information
- 4.2.2 GSK Business Overview
- 4.2.3 GSK Influenza Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 GSK Influenza Vaccine Product Portfolio
- 4.2.5 GSK Recent Developments
- 4.3 Sanofi Pasteur
- 4.3.1 Sanofi Pasteur Company Information
- 4.3.2 Sanofi Pasteur Business Overview
- 4.3.3 Sanofi Pasteur Influenza Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Sanofi Pasteur Influenza Vaccine Product Portfolio
- 4.3.5 Sanofi Pasteur Recent Developments
- 4.4 Mylan
- 4.4.1 Mylan Company Information
- 4.4.2 Mylan Business Overview
- 4.4.3 Mylan Influenza Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Mylan Influenza Vaccine Product Portfolio
- 4.4.5 Mylan Recent Developments
- 4.5 Hulan Bio
- 4.5.1 Hulan Bio Company Information
- 4.5.2 Hulan Bio Business Overview
- 4.5.3 Hulan Bio Influenza Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Hulan Bio Influenza Vaccine Product Portfolio
- 4.5.5 Hulan Bio Recent Developments
- 4.6 AstraZeneca
- 4.6.1 AstraZeneca Company Information
- 4.6.2 AstraZeneca Business Overview
- 4.6.3 AstraZeneca Influenza Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 AstraZeneca Influenza Vaccine Product Portfolio
- 4.6.5 AstraZeneca Recent Developments
- 4.7 CCBIO
- 4.7.1 CCBIO Company Information
- 4.7.2 CCBIO Business Overview
- 4.7.3 CCBIO Influenza Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 CCBIO Influenza Vaccine Product Portfolio
- 4.7.5 CCBIO Recent Developments
5 Global Influenza Vaccine Market Scenario by Region
- 5.1 Global Influenza Vaccine Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Influenza Vaccine Sales by Region: 2021-2032
- 5.2.1 Global Influenza Vaccine Sales by Region: 2021-2026
- 5.2.2 Global Influenza Vaccine Sales by Region: 2027-2032
- 5.3 Global Influenza Vaccine Revenue by Region: 2021-2032
- 5.3.1 Global Influenza Vaccine Revenue by Region: 2021-2026
- 5.3.2 Global Influenza Vaccine Revenue by Region: 2027-2032
- 5.4 North America Influenza Vaccine Market Facts & Figures by Country
- 5.4.1 North America Influenza Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Influenza Vaccine Sales by Country (2021-2032)
- 5.4.3 North America Influenza Vaccine Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Influenza Vaccine Market Facts & Figures by Country
- 5.5.1 Europe Influenza Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Influenza Vaccine Sales by Country (2021-2032)
- 5.5.3 Europe Influenza Vaccine Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Influenza Vaccine Market Facts & Figures by Country
- 5.6.1 Asia Pacific Influenza Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Influenza Vaccine Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Influenza Vaccine Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Influenza Vaccine Market Facts & Figures by Country
- 5.7.1 South America Influenza Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Influenza Vaccine Sales by Country (2021-2032)
- 5.7.3 South America Influenza Vaccine Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.7.7 Colombia
- 5.8 Middle East and Africa Influenza Vaccine Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Influenza Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Influenza Vaccine Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Influenza Vaccine Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Influenza Vaccine Sales by Type (2021-2032)
- 6.1.1 Global Influenza Vaccine Sales by Type (2021-2032) & (M Doses)
- 6.1.2 Global Influenza Vaccine Sales Market Share by Type (2021-2032)
- 6.2 Global Influenza Vaccine Revenue by Type (2021-2032)
- 6.2.1 Global Influenza Vaccine Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Influenza Vaccine Revenue Market Share by Type (2021-2032)
- 6.3 Global Influenza Vaccine Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Influenza Vaccine Sales by Application (2021-2032)
- 7.1.1 Global Influenza Vaccine Sales by Application (2021-2032) & (M Doses)
- 7.1.2 Global Influenza Vaccine Sales Market Share by Application (2021-2032)
- 7.2 Global Influenza Vaccine Revenue by Application (2021-2032)
- 7.2.1 Global Influenza Vaccine Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Influenza Vaccine Revenue Market Share by Application (2021-2032)
- 7.3 Global Influenza Vaccine Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Influenza Vaccine Value Chain Analysis
- 8.1.1 Influenza Vaccine Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Influenza Vaccine Production Mode & Process
- 8.2 Influenza Vaccine Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Influenza Vaccine Distributors
- 8.2.3 Influenza Vaccine Customers
9 Global Influenza Vaccine Analyzing Market Dynamics
- 9.1 Influenza Vaccine Industry Trends
- 9.2 Influenza Vaccine Industry Drivers
- 9.3 Influenza Vaccine Industry Opportunities and Challenges
- 9.4 Influenza Vaccine Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst